The trial included both G3 NEC and NETs, with only 57 percent of tumours being poorly differentiated, and a relatively low overall Ki67 index of 48% in the TemCap arm and 60% in the EP arm. This evidence concerns the gene MKI67 and neuroendocrine carcinoma.